Link to this page
Physician Data Query
| Preferred Name | telavancin hydrochloride | |
| Synonyms |
vancomycin, N(sup 3'')-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride TD-6424 3S,6R,7R,22R,23S,26S,36R,38ar)-3-(2-amino-2-oxoethyl)-10,19-dichloro-44-((2-O-(3-((2-(decylamino)ethyl)amino)-3-C-methyl-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)-.beta.-D-glucopyranosyl)oxy)-7,22,28,30,32-pentahydroxy-6-(((2R)-4-methyl-2-(methylamino) Vibativ |
|
| Definitions |
The hydrochloride salt form of telavancin, a lipoglycopeptide and a semisynthetic derivative of vancomycin with antibacterial activity against gram-positive bacteria. Like vancomycin, telavancin binds tightly to the D-alanyl-D-alanine residue of cell wall precursors, thereby interfering with bacterial cell wall synthesis. In addition, the lipophilic moiety of telavancin may interact with the lipid bilayer in the bacterial cell membrane, thereby compromising the integrity of cell membrane and causing cell membrane depolarization. This novel mechanism of action may contribute to telavancin's rapid bactericidal activity and its improved activity over vancomycin against some antibiotic resistance gram-positive bacteria. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87636" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87636" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000698126 |
|
| altLabel |
vancomycin, N(sup 3'')-(2-(decylamino)ethyl)-29-(((phosphonomethyl)amino)methyl)-, monohydrochloride TD-6424 3S,6R,7R,22R,23S,26S,36R,38ar)-3-(2-amino-2-oxoethyl)-10,19-dichloro-44-((2-O-(3-((2-(decylamino)ethyl)amino)-3-C-methyl-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl)-.beta.-D-glucopyranosyl)oxy)-7,22,28,30,32-pentahydroxy-6-(((2R)-4-methyl-2-(methylamino) Vibativ
|
|
| cui |
C2722634 C2730005 C1453643
|
|
| DATE FIRST PUBLISHED |
2011-03-29
|
|
| Date last modified |
2011-04-06
|
|
| definition |
The hydrochloride salt form of telavancin, a lipoglycopeptide and a semisynthetic derivative of vancomycin with antibacterial activity against gram-positive bacteria. Like vancomycin, telavancin binds tightly to the D-alanyl-D-alanine residue of cell wall precursors, thereby interfering with bacterial cell wall synthesis. In addition, the lipophilic moiety of telavancin may interact with the lipid bilayer in the bacterial cell membrane, thereby compromising the integrity of cell membrane and causing cell membrane depolarization. This novel mechanism of action may contribute to telavancin's rapid bactericidal activity and its improved activity over vancomycin against some antibiotic resistance gram-positive bacteria. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C87636" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C87636" NCI Thesaurus)
|
|
| LT |
TRD
|
|
| NCI ID |
C87636
|
|
| notation |
CDR0000698126
|
|
| ORIG STY |
Drug/agent
|
|
| prefLabel |
telavancin hydrochloride
|
|
| tui |
T109 T195 T116 T121
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |